Literature DB >> 21883029

Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms.

Peter Johansson1, Ruben Mesa, Robyn Scherber, Johanna Abelsson, Jan Samuelsson, Gunnar Birgegård, Björn Andréasson.   

Abstract

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) is a validated quality of life (QoL) instrument. In our Swedish cohort of 114 patients the symptomatic burden was found to be severe, with fatigue reported in 88% of the patients and reduced QoL in the majority of patients. Patients with primary myelofibrosis had the highest scores, low QoL, for most MPN-SAF items, compared to patients with polycythemia vera and essential thrombocythemia. Higher age showed significant associations with the BFI (Brief Fatigue Inventory) score, early satiety, concentration problems, dizziness, insomnia, cough and weight loss. Blood values, disease duration and myelosuppressive treatment did not significantly associate with any of the MPN-SAF items, with the exception of higher hemoglobin, which correlated with sad mood. Male patients with MPN scored significantly higher as regards sexual problems and weight loss compared to female patients. Overall, the MPN-SAF was found to be a valid instrument for assessing symptomatic burden among this population.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21883029     DOI: 10.3109/10428194.2011.619608

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  17 in total

1.  Diagnosis and Management of Polycythemia Vera: Proceedings from a Multidisciplinary Roundtable.

Authors:  Lisa A Raedler
Journal:  Am Health Drug Benefits       Date:  2014-10

Review 2.  Key Role of Inflammation in Myeloproliferative Neoplasms: Instigator of Disease Initiation, Progression. and Symptoms.

Authors:  Laura F Mendez Luque; Amanda L Blackmon; Gajalakshmi Ramanathan; Angela G Fleischman
Journal:  Curr Hematol Malig Rep       Date:  2019-06       Impact factor: 3.952

3.  Assessment of Quality of Life following Allogeneic Stem Cell Transplant for Myelofibrosis.

Authors:  Jeanne Palmer; Heidi E Kosiorek; Christine Wolschke; Veena D S Fauble; Richard Butterfield; Holly Geyer; Robyn M Scherber; Amylou C Dueck; Allison Gathany; Ruben A Mesa; Nicolaus Kroger
Journal:  Biol Blood Marrow Transplant       Date:  2019-07-06       Impact factor: 5.742

4.  Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine-Results from the Italian 'Back to Life' project.

Authors:  Francesca Palandri; Giulia Benevolo; Alessandra Iurlo; Elisabetta Abruzzese; Angelo M Carella; Chiara Paoli; Giuseppe A Palumbo; Massimiliano Bonifacio; Daniela Cilloni; Alessandro Andriani; Attilio Guarini; Diamante Turri; Elena Maria Elli; Antonietta Falcone; Barbara Anaclerico; Pellegrino Musto; Nicola Di Renzo; Mario Tiribelli; Renato Zambello; Caterina Spinosa; Alessandra Ricco; Letizia Raucci; Bruno Martino; Mario Annunziata; Silvia Pascale; Anna Marina Liberati; Giorgio La Nasa; Margherita Maffioli; Massimo Breccia; Novella Pugliese; Silvia Betti; Gianfranco Giglio; Antonietta Cappuccio; Luigi Reale
Journal:  Qual Life Res       Date:  2018-03-08       Impact factor: 4.147

5.  A new internet-based tool for reporting and analysing patient-reported outcomes and the feasibility of repeated data collection from patients with myeloproliferative neoplasms.

Authors:  Nana Brochmann; Ann-Dorthe Zwisler; Mette Kjerholt; Esben Meulengracht Flachs; Hans Carl Hasselbalch; Christen Lykkegaard Andersen
Journal:  Qual Life Res       Date:  2015-09-11       Impact factor: 4.147

Review 6.  How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera.

Authors:  Andreas Reiter; Claire Harrison
Journal:  Curr Hematol Malig Rep       Date:  2016-10       Impact factor: 3.952

Review 7.  Novel and emerging therapies for the treatment of polycythemia vera.

Authors:  Srdan Verstovsek; Rami S Komrokji
Journal:  Expert Rev Hematol       Date:  2014-10-29       Impact factor: 2.929

Review 8.  Ruxolitinib for the treatment of patients with polycythemia vera.

Authors:  Jean-Jacques Kiladjian; Elliott F Winton; Moshe Talpaz; Srdan Verstovsek
Journal:  Expert Rev Hematol       Date:  2015-05-17       Impact factor: 2.929

Review 9.  Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F.

Authors:  Brady L Stein; Stephen T Oh; Dmitriy Berenzon; Gabriela S Hobbs; Marina Kremyanskaya; Raajit K Rampal; Camille N Abboud; Kenneth Adler; Mark L Heaney; Elias J Jabbour; Rami S Komrokji; Alison R Moliterno; Ellen K Ritchie; Lawrence Rice; John Mascarenhas; Ronald Hoffman
Journal:  J Clin Oncol       Date:  2015-08-31       Impact factor: 44.544

10.  Clinical and Disease Characteristics From REVEAL at Time of Enrollment (Baseline): Prospective Observational Study of Patients With Polycythemia Vera in the United States.

Authors:  Michael R Grunwald; Brady L Stein; Ralph V Boccia; Stephen T Oh; Dilan Paranagama; Shreekant Parasuraman; Philomena Colucci; Ruben Mesa
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2018-08-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.